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Background and Purpose—Biomarkers predicting mortality and functional outcome in stroke may be clinically helpful in
identification of patients likely to benefit from intervention. Activated leukocyte cell adhesion molecule (ALCAM) is
upregulated during neuroinflammation; we investigated whether ALCAM concentrations are associated with long-term
mortality after ischemic stroke.
Methods—In 244 patients with acute ischemic stroke (age 6913 years), samples of ALCAM were obtained serially from
presentation to Day 5 and after 6 months. Patients with overt ischemic heart disease and atrial fibrillation were excluded.
The patients were followed for 47 months with all-cause and cardiovascular mortality as end points.
Results—At follow-up, 72 patients (29%) had died, 43 due to cardiovascular causes. Patients with ALCAM in the fourth
quartile (46.8 ng/mL) at admission had a significantly poorer survival rate on univariate analysis (P0.001); other
time points did not add further but provided similar prognostic information. In multivariate analysis, after adjustment
for age, stroke severity, C-reactive protein levels, troponin T levels, and heart and/or renal failure, ALCAM levels above
the fourth quartile remained an independent predictor of long-term mortality (adjusted hazard ratio, 2.05; 95% CI, 1.11
to 3.76; P0.021) and cardiovascular mortality (adjusted hazard ratio, 2.54; 95% CI, 1.06 to 6.07; P0.028).
Conclusions—ALCAM levels measured at admission of acute ischemic stroke are associated with long-term mortality. (Stroke.
2011;42:2453-2458.)
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Acute ischemic stroke is a leading cause of death andserious, long-term disability in adults.1 Effective treat-
ments are available, but such therapies are greatly dependent
on early diagnosis and assessment of stroke severity.1,2 Thus,
prompt identification of patients at increased risk for adverse
outcomes from ischemic stroke might target individuals
likely to benefit from intervention. In this context, rapidly
measurable biomarkers predicting mortality and functional
outcome in stroke would be clinically helpful.3
Although the pathogenesis of acute ischemic stroke is
multifactorial, several prognostically meaningful aspects may
be assessed with objective biomarkers. For example, inflam-
mation is thought to play a critical role in several aspects of
pathophysiology and disease exacerbation in acute ischemic
stroke.4–6 Inflammation could promote plaque destabilization
within a carotid atherosclerotic lesion, resulting in emboliza-
tion and subsequent cerebral stroke, and inflammation may
progress within freshly infarcted cerebral tissue, further
promoting tissue damage.
Cell adhesion molecules are involved in attraction and
recruitment of leukocytes into the site of inflammation and
tissue damage, promoting transendothelial migration that
involves a series of well-coordinated events between in-
flamed endothelium and activated leukocytes.5,7 Firm adhe-
sion of leukocytes to the endothelial cells as well as leukocyte
activation is mediated by receptors of the immunoglobulin
gene superfamily. Given the involvement of cell adhesion
molecules in atherogenesis and response to tissue damage as
well as the high circulating levels of their soluble isoforms,
soluble cell adhesion molecules have been shown to be
associated with disease severity and outcome in various
cardiovascular (CV) disorders, including stroke.8,9 Thus, high
levels of soluble intracellular adhesion molecule-1 and vas-
cular cell adhesion molecule-1 have been detected in patients
with ischemic stroke and in particular, intracellular adhesion
molecule-1 levels on admission have been associated with
adverse outcome in these patients.9–13
Also belonging to the immunoglobulin gene superfamily is
activated leukocyte cell adhesion molecule (ALCAM), also
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denoted CD166. ALCAM is upregulated substantially during
inflammation and replaces vascular cell adhesion molecule-1
during transmigration of leukocytes across central nervous
system endothelium.14 ALCAM has been shown to be suit-
able as a prognostic marker for different types of cancer,15 but
at present, there are no data on ALCAM levels as a biomarker
in CV disorders. Based on its role in neuroinflammation, we
prospectively studied patients with acute ischemic stroke to
(1) describe the level of ALCAM during the early phase of
ischemic stroke; and to (2) examine whether ALCAM con-
centrations are associated with long-term mortality after
ischemic stroke.
Subjects and Methods
Between August 2003 and October 2004, 790 patients with acute
ischemic stroke admitted to the Department of Neurology at Odense
University Hospital, Odense, Denmark, were consecutively screened
for inclusion in the study.16 Patients with overt ischemic heart
disease (n177; ie, any prior myocardial infarction, stable or
unstable angina pectoris, pathological Q-waves on the baseline
electrocardiogram, previous coronary angioplasty or coronary by-
pass surgery), patients with current atrial fibrillation (n132), or
patients with onset of stroke symptoms 7 days before admission
(n75) were not included. In addition, 115 patients were excluded
because of technical reasons or lack of compliance and 47 patients
were unwilling to participate, rendering 244 patients eligible for
inclusion in the study.
Evaluation of each study subject was performed by a senior
neurologist blinded to the biomarkers; the presence of intracerebral
or subarachnoid hemorrhage was ruled out by CT at the time of
admission. Patient demographics along with past and present clinical
history including medication were obtained by interview. Renal
failure was defined as plasma creatinine120 M. Heart failure was
considered present if the patients had a left ventricular systolic
ejection fraction50% and/or if a patient had previously been given
the diagnosis of heart failure by a physician. If the patient was unable
to take part in the interview, relatives participated. Medical history
was retrieved by reviewing hospital records. Severity of the index
stroke was assessed using the Scandinavian Stroke Scale.17 Stroke
subtypes were classified according to the Oxfordshire Community
Stroke Project.18 The study was approved by the local ethics
committee and by the National Danish Registry Board.
Laboratory Analyses
Peripheral venous blood was collected immediately at admission,
subsequently up to 5 days after admission, and once at 6 months. The
specimens were collected in heparin-containing tubes, centrifuged
for 10 minutes at 2000 g within 4 hours of collection, stored at
80°C, and thawed 3 times before analyses. Plasma ALCAM was
quantified by an enzyme immunoassay in duplicate using commer-
cially available matched antibodies (R&D Systems, Minneapolis,
MN). The plasma samples were diluted 80 times before enzyme
immunoassay measurements, minimizing any influence of different
matrices. The inter- and intra-assay coefficient of variation was
10%. Cardiac troponin T (cTnT) was determined on an Elecsys
1010 (Roche Diagnostics Boehringer Mannheim, Mannheim, Ger-
many) as previously described.16 The inter- and intra-assay coeffi-
cient of variation was5%. As diagnostic cutoff value, we used 0.03
g/L, reflecting the lowest cutoff value providing 10% impreci-
sion. C-reactive protein (CRP) and creatinine (Jaffe method) were
measured on Modular Analytics P (Roche Diagnostics, Basel,
Switzerland). The inter- and intra-assay coefficients of variation
were 5%.
Follow-Up
The primary outcome measure was all-cause mortality. Mortality
data were obtained from the Danish Central Personal Registry, which
registered all deaths in Denmark within 2 weeks. Cause-specific
mortality was divided into CV (n43), cancer (n13), and other
(n16, mainly chronic obstructive pulmonary disease [n4] and
pneumonia [n7]). For statistical analysis, we focus on CV death
and only as a group because a further division into more cause-
specific groups will result in power issues and possibly obscure our
findings. The median follow-up time was 4.4 years (interquartile
range, 3.7 to 4.9 years) and follow-up was complete in 100%
of subjects.
Statistics
To evaluate the difference of demographic and clinical characteris-
tics, Fisher exact test, Wilcoxon rank sum test, and Student t test
were applied where appropriate. Differences in the levels of
ALCAM from Day 0 to 6 were evaluated by univariate repeated-
measures analysis of variance a priori and Wilcoxon signed rank test
a posteriori. Multivariable stepwise linear regression analyses were
performed to identify determinants of ALCAM levels (log-
transformed) including variables associated with increased ALCAM
in Table 1 (all variables with P0.2 were included).
For mortality analyses, concentrations of ALCAM at the time of
presentation and over the first several days after presentation were
examined as a function of long-term follow-up. Receiver operating
characteristic curves were established for ALCAM as a predictor of
death at follow-up. Kaplan-Meier analysis with log-rank test was
performed to compare mortality rate in quartiles of ALCAM. The
Cox proportional hazards model was applied to assess the effect of
ALCAM on survival at follow-up. Baseline variables were included
in the adjusted model if they were imbalanced between patients that
survived and those who died, as indicated by a univariate probability
value 0.05. The following variables were entered into the multi-
variable model: age, presence of heart and/or renal failure, Scandi-
navian Stroke Scale score, CRP, and TnT levels 0.03 g/L. In all
Table 1. Baseline Characteristics of Study Patients
Variable
Age, y 6913
Men 129 (53%)
History
Previous ischemic stroke 50 (21%)
Hypertension 133 (55%)
Diabetes mellitus 29 (12%)
Lacunar infarction 116 (48%)
Total anterior circulation infarction 12 (5%)
Partial anterior circulation infarction 81 (31%)
Posterior circulation infarction 33 (14%)
Smoking 124 (51%)
Prior heart and/or renal failure 32 (13%)
Physical examination
Pulse 7815
Systolic blood pressure, mm Hg 17529
Diastolic blood pressure, mm Hg 9317
Scandinavian Stroke Scale score 47 (36–53)
Laboratory findings
Troponin T 0.03 g/L 17 (7%)
Hemoglobin, g/dL 8.581.06
Creatinine, mg/dL 91 (80–103)
C-reactive protein, mg/L 5 (5–14)
Proportions are given as no. and (%). Continuous variables are given as
meanstandard deviation or median and interquartile range depending on
distribution.
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tests, a probability value 0.05 was considered statistically
significant.
Results
Patient Characteristics
Baseline clinical characteristics of the study subjects are
shown in Table 1. At presentation, the median ALCAM
concentration in the group as a whole was 39.9 ng/mL
(interquartile range, 34.2 to 46.8 ng/mL). In a multivariable
stepwise linear regression model, the following were found to
be independent predictors of presenting ALCAM concentra-
tion in acute patients with ischemic stroke: age (t4.03;
P0.001), gender (t2.74, P0.007), and a history of
heart and/or renal failure (t2.24, P0.026).
When examining the temporal pattern of ALCAM from
symptom onset, we found no time-dependent difference
during the first 5 days (Figure 1). However, a significant
increase in ALCAM levels was observed after 6 months as
compared with baseline (P0.001; Figure 1). The reason for
this pattern is not clear, but because cerebral atheroscleroses
are likely to be common features in most of this homogenous
group of patients with ischemic stroke, it could potentially
reflect accelerated atherogenesis after the vascular events.
ALCAM and Outcomes After Ischemic Stroke
Univariate Analyses
At follow-up (median, 4.4 years), 72 patients (29%) had died.
ALCAM concentrations at admission were significantly
higher in decedents than in survivors and notably, the same
pattern was also seen for the other time points during
follow-up (Table 2).
Receiver operating characteristic analysis indicated that the
level of ALCAM at admission had reasonable accuracy for
the prediction of mortality at follow-up (Table 2); ALCAM
levels from different days after admission had largely similar
areas under the curve values (Table 2), underscoring the
stability of ALCAM levels during the early phase after acute
ischemic stroke. To this point, the mean ( SD) intraindi-
vidual variability in ALCAM levels during the first 5 days
was 10.2%5.4% (range, 1.1 to 48.9). Because the area
under the curve for ALCAM was the same through the first
several days after presentation, we examined levels at admis-
sion for identifying the cut point for ALCAM as a predictor
of death. In quartile analysis, an apparent threshold effect was
observed in patients at or above the highest quartile for
ALCAM (46.8 ng/mL). This was confirmed in Kaplan-
Meier analyses using these quartiles (Figure 2A). An
ALCAM concentration 46.8 ng/mL had 45% sensitivity,
84% specificity, positive predictive value of 54%, and nega-
tive predictive value of 78% for death at 1 year.
When looking at clinical variables in relation to high and
low ALCAM levels (ie, fourth quartile versus the lower 3), a
few associations were noted (Table 3). Patients with in-
creased circulating ALCAM concentrations were older and
had decreased hemoglobin levels. They also tended to be
women and had a history of heart and/or renal failure. In
contrast, no significant differences in ALCAM levels were
observed for other variables, including stroke subtypes, pre-
vious ischemic stroke, hypertension, diabetes mellitus, blood
pressure, or levels of cTnT, creatinine, and CRP.
Multivariate Analyses
The unadjusted hazard ratio for fourth quartile ALCAM and
other variables associated with increased mortality are given
in Table 4. In multivariate analysis, baseline variables (Table
1) were included if they were imbalanced between patients
who survived and those who died (ie, P0.05 in univariate
analyses). After adjustment for these variables (ie, Scandina-
vian Stroke Scale score, TnT, CRP, age, and prior heart
and/or renal failure), ALCAM levels in the fourth quartile
remained an independent predictor of long-term mortality
Figure 1. Box plots showing ALCAM levels from onset of symp-
toms (Day 0). ***P0.001 vs Day 0. ALCAM indicates activated
leukocyte cell adhesion molecule.
Table 2. Plasma ALCAM Levels in Survivors and Decedents and Area Under the Receiver Operating
Characteristic Curves (AUC) the First 5 Days After Admission and After 6 Months
Survivors Decedents AUC (95% CI) P
ALCAM admission, n203 38.7 (34.1–43.1) 43.8 (38.1–51.9)† 0.67 (0.58–0.75) 0.001
Day 1 after admission, n226 38.9 (33.3–43.4) 43.2 (36.5–49.8)† 0.65 (0.57–0.73) 0.001
Day 2 after admission, n225 38.7 (34.1–43.1) 44.5 (37.0–50.7)† 0.66 (0.58–0.74) 0.001
Day 3 after admission, n222 38.4 (32.6–43.3) 44.6 (37.7–52.7)† 0.71 (0.63–0.78) 0.001
Day 4 after admission, n205 38.5 (33.2–44.1) 43.9 (39.4–49.4)† 0.67 (0.59–0.75) 0.001
Day 5 after admission, n169 38.0 (32.8–44.4) 43.9 (37.2–50.1)* 0.64 (0.55–0.73) 0.005
6-mo control, n195 42.1 (36.7–47.7) 45.2 (41.7–56.0)* 0.66 (0.57–0.75) 0.002
ALCAM indicates activated leukocyte cell adhesion molecule; AUC, area under the receiver operating characteristic curves; CI,
confidence interval.
*P0.01.
†P0.001 decedents vs survivors.
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(adjusted hazard ratio, 2.05; 95% CI, 1.11 to 3.76; P0.021;
Table 4).
ALCAM in Relation to the Cause of Death
During follow-up, 43 patients died of CV causes, 13 patients
died of cancer, and 16 patients died of other causes. The
highest ALCAM levels were observed in cancer (median,
49.4; interquartile range, 38.9 to 52.7; P0.037 versus
survivors) followed by CV (44.8 [38.4 to 51.8; P0.001
versus survivors) and other causes (42.6 [34.0 to 51.2];
P0.3 versus survivors). ALCAM was a significant predictor
of CV death, also after adjustment in multivariate analysis
(Table 4). Cancer did not remain significant in multivariate
analysis due to low numbers. Figure 2B shows the Kaplan-
Meier analyses for CV death. As can be seen, the early
divergence in the fourth quartile was mostly due CV death,
and this association with “short-term” mortality supports that
ALCAM may be specific to stroke-related mortality and not
coincidentally associated.
Discussion
Among a cohort of patients with acute ischemic stroke, we
found that plasma levels of ALCAM were consistently higher
across the first several days after stroke in those patients who
subsequently experienced an adverse outcome. Furthermore,
ALCAM values remained elevated after 6 months in dece-
dents and displayed only minor intraindividual variability
indicating suitability as a stable biomarker for adverse events
in these patients. Importantly, elevated ALCAM levels re-
mained an independent predictor of all-cause and CV mor-
tality also after adjustment in multivariate analysis for estab-
lished risk factors such as age, the presence of heart and renal
failure, cTnT and CRP levels, and severity of the index
stroke. To the best of our knowledge, this is the first report
assessing the prognostic value of circulating ALCAM levels
in cerebrovascular disease, implicating a potential pathogenic
role in the development of atherosclerosis and its major
clinical consequences such as stroke.
The dynamic processes that take part during the develop-
ment of an acute ischemic stroke involve plaque destabiliza-
tion, embolization of thrombus materials, and tissue damage
within the brain. These processes involve inflammation as a
common mediator, and molecules that could reflect these
inflammatory pathways have been used as biomarkers to
predict the evolution of ischemic stroke.5,6,9 Thus, several
studies have shown an association between leukocyte count,
fibrinogen, or CRP and a higher risk following stroke.19–21
Circulating adhesion molecules reflect the inflammatory in-
teraction between endothelial cells and leukocytes. Although
there are several data on the association between these
molecules and adverse outcome among patients with coro-
nary artery disease, acute coronary syndromes, and heart
failure, there are limited data of their ability to predict
long-term mortality in patients with ischemic stroke. Camp-
bell et al showed that soluble vascular cell adhesion
Figure 2. Kaplan-Meier curves showing the cumu-
lative incidence of (A) all-cause and (B) cardiovas-
cular (CV) mortality during the entire study (median
follow-up, 4.4 years; interquartile range, 3.7 to 4.9
years) according to quartiles of ALCAM at admis-
sion. ALCAM indicates activated leukocyte cell
adhesion molecule.
Table 3. Baseline Characteristics of Study Patients According
to ALCAM at Presentation
Variable
ALCAM
46.8
ALCAM
46.8 P
Age, y 6712 7413 0.001
Men 80 (53%) 19 (39%) 0.05
History
Previous ischemic stroke 30 (20%) 9 (18%) 0.80
Hypertension 83 (55%) 29 (59%) 0.64
Diabetes mellitus 15 (10%) 8 (16%) 0.10
Lacunar infarction 80 (53%) 21 (43%) 0.30
Total anterior circulation 5 (3%) 2 (4%) 0.77
Partial anterior circulation 47 (31%) 17 (35%) 0.54
Posterior circulation infarction 18 (12%) 7 (14%) 0.60
Smoking 71 (53%) 25 (51%) 0.83
Prior heart and/or renal
failure
16 (11%) 12 (25%) 0.02
Physical examination
Pulse 7715 7815 0.56
Systolic blood pressure,
mm Hg
17529 17732 0.83
Diastolic blood pressure,
mm Hg
9317 9318 0.94
Scandinavian Stroke
Scale score
48 (37–53) 46 (37–53) 0.50
Laboratory findings
Troponin T 0.03 g/L 9 (6%) 6 (12%) 0.15
Hemoglobin, g/dL 8.640.98 8.021.16 0.001
Creatinine, mg/dL 88 (78–101) 93 (81–107) 0.10
C-reactive protein, mg/L 5.0 (5.0–11.0) 7.0 (5.0–18.0) 0.31
Proportions are given as no. and (%). Continuous variables are given as
meanSD or median and interquartile range depending on distribution.
ALCAM indicates activated leukocyte cell adhesion molecule; SD, standard
deviation.
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molecule-1 was associated with recurrent stroke in patients
with previous stroke or transient ischemic attack.11 In a small
study, Blum et al showed that patients with acute ischemic
stroke who improved clinically during the first days of
hospitalization demonstrated a decrease in circulating levels
of E-selectin, intracellular adhesion molecule-1, and vascular
cell adhesion molecule-1.10 However, data regarding ALCAM
in stroke are lacking.
Although CRP and cTnT are reliable biomarkers in ische-
mic stroke, it is unlikely that these biomarkers could reflect
all pathogenic processes involved in this complex disorder.
Our finding in the present study, with a different pattern of
ALCAM that was not correlated with CRP or cTnT, may
suggest that ALCAM reflects other pathogenic processes than
those mirrored by more established biomarkers. Certainly,
ALCAM has been implicated in stabilization of the immuno-
logic synapse, T cell activation, and monocyte transendothe-
lial migration,22–25 and has previously been found to give
prognostic information in malignancies.15 We report the value
of ALCAM levels for prognostication after acute ischemic
stroke. Plasma ALCAM displayed very low intraindividual
variation during the acute phase and circulates at high levels
making it a potentially reliable biomarker for clinical use.
However, although our data may suggest that ALCAM is
relatively specific and will identify individuals who truly are
at risk, there will still be a high mortality rate among patients
with low ALCAM levels, limiting its use.
Although the present study cannot inform whether ALCAM
plays a mechanistic role in complications after stroke, it is
tempting to hypothesize that elevated ALCAM values are
pathogenic in this setting. The lack of association of ALCAM
with stroke severity could suggest that increased ALCAM
levels may predispose individuals to an adverse outcome
rather than merely reflect the ischemic insult. Indeed, acute or
chronic inflammatory diseases preceding stroke may contrib-
ute to outcome.26,27 Furthermore, the recruitment of leuko-
cytes and platelets in the cerebral microvasculature is widely
regarded as a pivotal step in the inflammatory response
associated with cerebral ischemia.5,6 Increased ALCAM lev-
els could therefore contribute directly to atherosclerosis and
its cerebrovascular complications by altering blood–brain
barrier function and accelerating the recruitment of leuko-
cytes into the cerebral microvasculature. In addition, experi-
mental studies implicate a role for CD4 and CD8 T cells in
cerebral microvascular dysfunction.28 Because ALCAM,
through its interaction with CD6 on T cells, is required for
optimal T cell activation (promoting an inflammatory T cell
phenotype), it might also contribute to inflammation and
tissue injury associated with brain ischemia through T cell-
mediated mechanisms.22,23,25 Highly relevant to the setting of
ischemic stroke, a recent study demonstrated that ALCAM
expression on blood–brain barrier cells was upregulated in
active multiple sclerosis and that ALCAM blockade restricted
the transmigration of CD4 T cells and monocytes across
blood–brain barrier endothelium, identifying ALCAM as a
potential target for the therapeutic dampening of
neuroinflammation.14
The current study has some limitations. The number of
events was relatively low, limiting the use of subanalyses.
Another stroke classification may have changed the ability of
ALCAM to identify stroke subtypes. The predictors of
mortality entered in multivariate analysis in the present study
were identified by univariate analysis. To avoid overfitting of
the model, other common risk factors for poor outcome in
patients with stroke, for example, smoking, were not in-
cluded. On the other hand, the longitudinal follow-up and
assessment of ALCAM levels in serial plasma samples
represent strengths of the current study. The exclusion criteria
represent both strength and a weakness. By excluding patients
with atrial fibrillation, overt ischemic heart disease, or pa-
tients with onset of stroke symptoms 7 days before admis-
sion, all states characterized by an increased inflammatory
Table 4. The Effects of ALCAM on All-Cause and CV Mortality
All-Cause Mortality (n72) CV Mortality (n43)
Variable Wald HR (95% CI) P Wald HR (95% CI) P
Univariate analysis
ALCAM (Q4 vs Q1–Q3) (admission) 18.7 3.01 (1.86–5.18) 0.001 13.6 3.43 (1.78–6.61) 0.001
SSS score 15.0 0.97 (0.96–0.99) 0.001 23.0 0.95 (0.94–0.97) 0.001
Troponin T 0.03 g/L 28.1 5.15 (2.81–9.45) 0.001 17.1 5.15 (2.37–11.19) 0.001
Log C-reactive protein 16.7 2.91 (1.74–4.86) 0.001 10.8 3.01 (1.56–5.82) 0.001
Age/10 27.4 1.77 (1.43–2.19) 0.001 19.5 1.89 (1.43–2.51) 0.001
Prior heart and/or renal failure 19.9 3.31 (1.96–5.61) 0.001 13.5 3.50 (1.79–6.85) 0.001
Multivariate analysis
ALCAM (Q4 vs Q1–Q3) 5.0 2.01 (1.09–3.69) 0.030 4.8 2.54 (1.06–6.07) 0.028
SSS score 8.7 0.97 (0.95–0.99) 0.003 19.7 0.95 (0.92–0.97) 0.001
Troponin T 0.03 g/L 8.2 3.09 (1.43–6.71) 0.004 3.1 2.58 (0.90–7.43) 0.079
Log C-reactive protein 6.1 2.42 (1.20–4.89) 0.010 4.4 2.54 (1.06–6.07) 0.036
Age/10 6.5 1.42 (1.09–1.85) 0.009 6.6 1.58 (1.12–2.24) 0.010
Prior heart and/or renal failure 1.6 1.56 (0.79–3.09) 0.20 0.2 1.21 (0.48–3.08) 0.68
ALCAM indicates activated leukocyte cell adhesion molecule; CV, cardiovascular; HR, hazard ratio; Q, quartile; SSS, Scandinavian Stroke Scale; CI, confidence
interval.
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component, it seems likely that the ALCAM levels do not
merely reflect inflammatory responses in concurrent inflam-
matory disorders. However, the exclusion of many patients
also represents a weakness because the relevance of our
findings to the general and heterogeneous stroke population
remains unknown.
In the present study, we show that plasma levels of
ALCAM during acute ischemic stroke were associated with
all-cause and CV mortality during long-term follow-up.
ALCAM has some unique properties as compared with other
adhesion molecules such as the role in T cell activation and
involvement in neuroinflammation that could contribute to its
ability to predict adverse outcome in stroke and may also
implicate its role as a mediator in these processes. Our
findings suggest that ALCAM should be added to the list of
inflammatory biomarkers that should be further investigated
in CV disorders, including ischemic stroke. Although several
biomarkers are inferior to CRP and cTnT in patients with
ischemic stroke and other CV disorders, studies on other
markers may be of importance to characterize the network of
mediators that are involved in the development of these
complex disorders.
Disclosures
None.
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